낭포성 섬유증 치료제 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Cystic Fibrosis Therapeutics Market was valued at USD 15.7 billion in 2024 and is projected to grow at a CAGR of 15.9% from 2025 to 2034. The increasing prevalence of cystic fibrosis (CF) and the rising focus on effective treatment solutions have contributed significantly to market growth. The growing number of CF cases has heightened the need for early diagnosis and improved therapeutic options, driving demand for innovative treatments. Research and development investments have accelerated advancements in potential therapies, particularly CF transmembrane conductance regulator (CFTR) modulators, leading to an expanding pipeline of clinical trials. These efforts aim to enhance treatment effectiveness and address unmet medical needs, broadening growth opportunities in the market.

The global market is segmented into medication and non-medication categories. The medication segment, valued at USD 11.9 billion in 2023, is projected to generate USD 14 billion in revenue in 2024. It is expected to maintain its dominance throughout the forecast period, growing at a CAGR of 16.1%. This segment includes CFTR modulators, bronchodilators, anti-infective agents, mucolytic agents, pancreatic enzyme supplements, and other drug classes. The growing advancements in CF drug therapies, particularly CFTR modulators and other symptomatic treatments, have significantly boosted demand. These medications improve patient outcomes by targeting CF symptoms and genetic mutations. Increasing research and development investments continue to enhance treatment availability, strengthening the segment's position in the market. The expansion of personalized medicine and broader reimbursement support are also key factors fueling segment growth.

Based on age group, the market is divided into Below 18 years, 18-40 years, and 41 years and above. In 2024, the Below 18 years segment held the largest market share at 76.8%. The high occurrence of CF in children and adolescents has driven demand for early diagnosis and targeted therapies. Most cases are identified in early childhood, necessitating prompt intervention and specialized treatments. Growing access to improved diagnostic tools and innovative therapies further reinforces segment growth. Pediatric research and regulatory approvals also play a crucial role in ensuring continued dominance throughout the forecast period.

In 2024, the United States held a significant share of the North American cystic fibrosis therapeutics market, generating USD 10.5 billion, up from USD 8.9 billion in 2023, with a CAGR of 15.9%. The high prevalence of CF in the country has fueled the demand for effective treatments, supported by strong research and development initiatives aimed at managing the disease burden. Extensive funding from both government and private sectors continues to drive innovations in drug development, particularly in CFTR modulators and advanced therapies. Expanding treatment options through novel drug formulations further boosts market growth. Strong reimbursement policies and the presence of leading pharmaceutical companies contribute to the country's sustained leadership in the market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence rate of cystic fibrosis patient population
    • 3.2.1.2 Advancements in CFTR modulator therapy
    • 3.2.1.3 Growing investment in research and development
    • 3.2.1.4 Government support and initiatives
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Adverse side effects of current therapies
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Epidemology scenario
• 3.6 Regulatory landscape
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Drug class
    • 5.2.1.1 CFTR modulators
    • 5.2.1.2 Mucolytic agents
    • 5.2.1.3 Bronchodilators
    • 5.2.1.4 Anti-infective agents
    • 5.2.1.5 Pancreatic enzyme supplements
    • 5.2.1.6 Other drug classes
  • 5.2.2 Route of administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Inhalation
  • 5.2.3 Distribution channel
    • 5.2.3.1 Hospital pharmacies
    • 5.2.3.2 Retail pharmacies
    • 5.2.3.3 Online pharmacies
• 5.3 Non-medication

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Below 18 years
• 6.3 18 - 40 years
• 6.4 41 and above

Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Ireland
• 7.4 Asia Pacific
  • 7.4.1 India
  • 7.4.2 Japan
  • 7.4.3 Australia
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Alcresta Therapeutics
• 8.2 Baxter
• 8.3 Chiesi Farmaceutici S.p.A.
• 8.4 F. Hoffmann-La Roche
• 8.5 Gilead
• 8.6 Koninklijke Philips N.V.
• 8.7 Lupin
• 8.8 Monaghan Medical
• 8.9 Novartis AG
• 8.10 Savara
• 8.11 Sionna Therapeutics
• 8.12 Teva Pharmaceutical Industries
• 8.13 Vertex Pharmaceuticals